Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Inmunoterapia > DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista >

Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience
Authors: Rodriguez, J. (J)
Conde, E. (E.)
Gutierrez, A. (Antonio)
Arranz, R. (R.)
Gandarillas, M. (M.)
Leon, A. (Angel)
Ojanguren, J. (Jesús)
Sureda, A. (Anna)
Carrera, D. (D,)
Bendandi, M. (Maurizio)
Moraleda, J. (José)
Ribera, J.M. (José María)
Albo, C. (Carmen)
Morales, A. (Alfonso)
Garcia, J. (Juan Carlos)
Fernandez, P. (Pascual)
Cañigral, G. (G.)
Bergua, J. (J.)
Caballero, M.D. (M.D.)
Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO)
Keywords: Angioimmunoblastic T-cell lymphoma
Autologous transplantation
Issue Date: 2007
Publisher: John Wiley and Sons
Publisher version: http://bit.ly/u0j2sE
ISSN: 1600-0609
Citation: Rodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007 Apr;78(4):290-296.
Abstract
Abstract OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%). RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL. CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.
Permanent link: http://hdl.handle.net/10171/20016
Appears in Collections:DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Hematología y Hemoterapia - Artículos de revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:
File:  Eur J Haem 2007_78.pdf
Description: 
Size:  535,64 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.